They are already back-pedaling. Look at slide that says 2007 will be a tough year and already looking for generic user fees. LOL. The OGD handling of a generic for VPHM's Vancocin was a complete embarassment to them and will likely be overturned to some extent by FDA based on VPHM's legal and scientific briefs. The OGD's disclosure of a change in generic bioequivalence reguirements to an analyst prior to public disclsoure was downright criminal and should be investigated by the SEC.
Market Data 
Markets 
AI
